Sim Hwan-Hee, Ko Ju-Young, Gong Dal-Seong, Kim Dong-Wook, Kim Jung Jin, Lim Han-Kyu, Kim Hyun Jung, Oak Min-Ho
Department of Pharmacy, College of Pharmacy, Mokpo National University, Muan 58554, Republic of Korea.
Convergence Center for Green Anti-Aging Research, Muan 58554, Republic of Korea.
Int J Mol Sci. 2025 Aug 20;26(16):8051. doi: 10.3390/ijms26168051.
Taxifolin is a natural flavonoid found in a variety of plants, including Siberian larch () and milk thistle (), that has attracted attention for its multifaceted pharmacological properties, including cardioprotective effects. Through its antioxidant and anti-inflammatory activities, taxifolin has shown significant therapeutic potential in cardiovascular diseases such as atherosclerosis, myocardial ischemia, and diabetic cardiomyopathy. This review highlights the cardioprotective effects of taxifolin in preclinical models of atherosclerosis, ischemia/reperfusion injury, and diabetic cardiomyopathy. Taxifolin contributes to its cardioprotective effects through key mechanisms such as modulation of pathways such as PI3K/AKT and JAK2/STAT3, inhibition of NADPH oxidase, and modulation of nitric oxide production. Recent studies have shown that taxifolin can affect glucose metabolism by modulating sodium-glucose transporter (SGLT) expression, potentially enhancing the cardioprotective effects of SGLT2 inhibitors. Given the emerging role of SGLT2 inhibitors in the management of cardiovascular disease, further investigation of the interaction of this pathway with taxifolin may provide new therapeutic insights. Although taxifolin has multifaceted potential in the prevention and treatment of cardiovascular disease, further studies are needed to better understand its mechanisms and validate its efficacy in different disease stages. This review aims to provide a rationale for the clinical application of taxifolin-based cardiovascular therapies and suggest directions for future research.
紫杉叶素是一种天然黄酮类化合物,存在于多种植物中,包括西伯利亚落叶松和水飞蓟,因其多方面的药理特性(包括心脏保护作用)而受到关注。通过其抗氧化和抗炎活性,紫杉叶素在动脉粥样硬化、心肌缺血和糖尿病性心肌病等心血管疾病中显示出显著的治疗潜力。本综述重点介绍了紫杉叶素在动脉粥样硬化、缺血/再灌注损伤和糖尿病性心肌病临床前模型中的心脏保护作用。紫杉叶素通过关键机制发挥其心脏保护作用,如调节PI3K/AKT和JAK2/STAT3等信号通路、抑制NADPH氧化酶以及调节一氧化氮生成。最近的研究表明,紫杉叶素可通过调节钠-葡萄糖转运蛋白(SGLT)表达来影响葡萄糖代谢,这可能增强SGLT2抑制剂的心脏保护作用。鉴于SGLT2抑制剂在心血管疾病管理中的新作用,进一步研究该信号通路与紫杉叶素的相互作用可能会提供新的治疗思路。尽管紫杉叶素在心血管疾病的预防和治疗方面具有多方面的潜力,但仍需要进一步研究以更好地理解其机制并验证其在不同疾病阶段的疗效。本综述旨在为基于紫杉叶素的心血管治疗的临床应用提供理论依据,并为未来研究指明方向。